Search

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

EHA2025 Congress

Join us for the 30th EHA Congress, taking place in Milan from June 12–15, 2025, as we revolutionize the way we learn and connect in hematology.

Read more

Abstract submission

Abstract procedureThe official abstract submission closed on March 1, 2025 (23:59 CET).

Read more

Highlights of Past EHA (HOPE) MENA 2021

For the upcoming edition of the Highlights of Past EHA (HOPE) Middle East and North Africa (MENA), EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

Read more

Scientific networks

Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.

Read more